Synthetic Version of Popular Anticoagulant Poised for Clinical Trials


Newswise imageA synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement.